EQUIPOISE by Meditech is a pharmaceutical-grade Boldenone Undecylenate injectable formulation, characterized by its long-acting undecylenate ester and sustained-release pharmacokinetic profile. Boldenone undecylenate is a structurally modified testosterone derivative with an extensive research history in comparative anabolic-androgenic steroid pharmacology literature, distinguished by its favorable anabolic-to-androgenic ratio, low aromatization rate, and distinct erythropoietic activity profile.
 
✔ Key Research Insights
Studied for its sustained-release pharmacokinetic profile, with the undecylenate ester documented to maintain stable serum boldenone concentrations across extended inter-dose intervals in research subjects
Investigated for its effects on lean mass parameters and nitrogen retention via androgen receptor activation in documented clinical observations, noted for a comparatively gradual and consistent anabolic activity profile in research literature
Researched for its erythropoietic activity, with documented stimulation of erythropoietin production and associated effects on red blood cell count and oxygen-carrying capacity across subject populations
Examined for its documented appetite-stimulating effects in research subjects, a pharmacological characteristic of clinical interest distinguishing boldenone from other anabolic-androgenic compounds in comparative steroid research
Documented for its low aromatization rate relative to testosterone, associated with reduced estrogenic activity and minimal fluid retention in comparative pharmacology research
Manufactured by Meditech to pharmaceutical-grade purity and reliability standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: EQUIPOISE
Molecule: Boldenone Undecylenate
Concentration: 250 mg/mL
Appearance: Oil-based solution
Packing: Sterile 10 mL vial 
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Boldenone undecylenate is a long-estered anabolic-androgenic steroid structurally derived from testosterone through the introduction of a double bond between carbon positions 1 and 2, administered via intramuscular injection. In research subjects, the undecylenate ester undergoes gradual enzymatic hydrolysis following administration, releasing free boldenone into systemic circulation over an extended period comparable to other long-acting ester preparations. Boldenone exerts its primary pharmacological effects through androgen receptor binding in muscle and target tissues, with documented downstream influences on protein synthesis and nitrogen retention in research literature. Its modified structure results in a significantly lower rate of aromatization to estrogen relative to testosterone — estimated at approximately 50% of testosterone's aromatization rate in comparative pharmacological research — contributing to a comparatively reduced estrogenic activity profile across documented subject populations. A pharmacologically notable and clinically distinct characteristic of boldenone documented across research literature is its stimulatory effect on appetite, attributed to androgenic activity on hypothalamic appetite-regulating pathways. Erythropoietic stimulation via increased erythropoietin production has been consistently documented across boldenone research literature, with associated effects on red blood cell production and oxygen-carrying capacity noted as a relevant secondary pharmacological effect in research subject populations.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and consistency standards
Long-acting undecylenate ester formulation with a well-documented sustained-release pharmacokinetic profile in comparative anabolic steroid research
Structurally modified testosterone derivative with a distinct low-aromatization and erythropoietic activity profile referenced extensively in comparative anabolic-androgenic steroid pharmacology literature
Available in both multi-dose vial and single-dose ampoule formats for clinical administration flexibility
Widely referenced in anabolic pharmacology and veterinary-to-human research literature under the boldenone undecylenate and Equipoise designations